Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. (Record no. 14247)

MARC details
000 -LEADER
fixed length control field 02932nam a22003737a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 240723s20232023 xxu||||| |||| 00| 0 eng d
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code PMC10723519 [pmc]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 38105958
245 ## - TITLE STATEMENT
Title Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
251 ## - Source
Source MedRxiv : the Preprint Server for Health Sciences. 2023 Dec 04
252 ## - Abbreviated Source
Abbreviated source medRxiv. 2023 Dec 04
253 ## - Journal Name
Journal name medRxiv : the preprint server for health sciences
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2023
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Publication date 2023 Dec 04
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2024
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status epublish
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Medline status PubMed-not-MEDLINE
520 ## - SUMMARY, ETC.
Abstract Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint). Secondary endpoints include the presence of ctDNA, toxicity, clinical outcomes at 2-years and association of ctDNA and PIS with clinical outcomes. Forty-five women with TNBC and residual invasive disease after standard neoadjuvant chemotherapy were randomized to nivolumab, capecitabine, or the combination. Here we show that a combination of nivolumab plus capecitabine leads to a greater increase in PIS from baseline to week 6 (91%) compared with nivolumab (47%) or capecitabine (53%) alone (log-rank p = 0.08), meeting the pre-specified primary endpoint. In addition, the presence of circulating tumor DNA (ctDNA) was associated with disease recurrence, with no new safety signals in the combination arm. Our results provide efficacy and safety data on this combination in TNBC and support further development of PIS and ctDNA analyses to identify patients at high risk of recurrence.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Indexing Automated
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution Washington Cancer Institute
656 ## - INDEX TERM--OCCUPATION
Department Associate Dean for Research Development
656 ## - INDEX TERM--OCCUPATION
Department MedStar Health
657 ## - INDEX TERM--FUNCTION
Medline publication type Preprint
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Chitalia, Ami
Institution Code WCI
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Gallagher, Christopher
Institution Code WCI
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Schlam, Ilana
Institution Code WCI
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Swain, Sandra M
Institution Code MSH
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Tiwari, Shruti
790 ## - Authors
All authors Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1101/2023.12.04.23297559">https://dx.doi.org/10.1101/2023.12.04.23297559</a>
Public note https://dx.doi.org/10.1101/2023.12.04.23297559
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
              07/23/2024   38105958 38105958 07/23/2024 07/23/2024 Journal Article

Powered by Koha